Key features and details
- Rabbit polyclonal to Adiponectin (Biotin)
- Suitable for: ELISA, WB
- Reacts with: Human
- Conjugation: Biotin
- Isotype: IgG
Product nameAnti-Adiponectin antibody (Biotin)
See all Adiponectin primary antibodies
DescriptionRabbit polyclonal to Adiponectin (Biotin)
Tested applicationsSuitable for: ELISA, WBmore details
Species reactivityReacts with: Human
Highly pure (>98%) recombinant full length protein (Human).
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferConstituents: PBS, 0.1% BSA
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab17895 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.15 - 0.3 µg/ml. Used in conjunction with compatible secondary reagents, allows the detection of at least 0.2 ng/well of recombinant Acrp30.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant human Acrp30 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 27 kDa.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionImportant adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW.
Tissue specificitySynthesized exclusively by adipocytes and secreted into plasma.
Involvement in diseaseDefects in ADIPOQ are the cause of adiponectin deficiency (ADPND) [MIM:612556]. ADPND results in very low concentrations of plasma adiponectin.
Genetic variations in ADIPOQ are associated with non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]; also known as diabetes mellitus type 2. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
Sequence similaritiesContains 1 C1q domain.
Contains 1 collagen-like domain.
DomainThe C1q domain is commonly called the globular domain.
modificationsHydroxylated Lys-33 was not identified in PubMed:16497731, probably due to poor representation of the N-terminal peptide in mass fingerprinting.
HMW complexes are more extensively glycosylated than smaller oligomers. Hydroxylation and glycosylation of the lysine residues within the collagene-like domain of adiponectin seem to be critically involved in regulating the formation and/or secretion of HMW complexes and consequently contribute to the insulin-sensitizing activity of adiponectin in hepatocytes.
O-glycosylated. Not N-glycosylated. O-linked glycans on hydroxylysines consist of Glc-Gal disaccharides bound to the oxygen atom of post-translationally added hydroxyl groups. Sialylated to varying degrees depending on tissue. Thr-22 appears to be the major site of sialylation. Higher sialylation found in SGBS adipocytes than in HEK fibroblasts. Sialylation is not required neither for heterodimerization nor for secretion. Not sialylated on the glycosylated hydroxylysines. Desialylated forms are rapidly cleared from the circulation.
- Information by UniProt
- 30 kDa adipocyte complement related protein antibody
- 30 kDa adipocyte complement-related protein antibody
- ACDC antibody
ab17895 has not yet been referenced specifically in any publications.